Regardless of their treatment assignment in the parent study , patients were randomized @:@ to receive either open-label subcutaneous evolocumab @ mg every @ weeks with standard of care ( SOC ) ( evolocumab + SOC , n = @ ) or SOC alone ( n = @ ) .